CoChat
Sign Up
Cited by 74Traditional Chinese Medicine StudiesNatural Antidiabetic Agents StudiesMedical Research and Treatments

Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature

Open access
Chen, Yan-kun, Liu, Ting-ting, Teia, Farah Khameis Farag, Xie, Meng-zhou·2023·Frontiers in Endocrinology
DOI 10.3389/fendo.2023.1218880PMC PMC10433171
Open this paper in CoChat — free accountOpen PDF

Abstract

Obesity and diabetes are closely related metabolic disorders that have become major public health concerns worldwide. Over the past few decades, numerous studies have explored the underlying mechanisms of these disorders and identified various risk factors, including genetics, lifestyle, and dietary habits. Traditional Chinese Medicine (TCM) has been increasingly recognized for its potential to manage obesity and diabetes. Weight loss is difficult to sustain, and several diabetic therapies, such as sulfonylureas, thiazolidinediones, and insulin, might make it harder to lose weight. While lifestyle changes should be the primary approach for people interested in lowering weight, drugs are also worth investigating. Since some of the newer glucose-lowering medications that cause weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are additionally utilized or are under consideration for use as anti-obesity drugs, the frontier between glucose-lowering medication and weight loss drugs appears to be shifting. This review provides an overview of the literature on the underlying mechanisms of obesity and diabetes and the prospect of TCM in their management. We discuss the various TCM interventions, including acupuncture, herbal medicine, and dietary therapy, and their effects on metabolic health. We also highlight the potential of TCM in regulating gut microbiota, reducing inflammation, and improving insulin sensitivity. The findings suggest that TCM may provide a promising approach to preventing and managing obesity and diabetes. However, further well-designed studies are needed to confirm the efficacy and safety of TCM interventions and to elucidate their underlying mechanisms of action.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1218880

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Unhealthy dietary patterns characterized by high intakes of refined, high-glycemic load carbohydrates and low intakes of dietary fiber play a crucial role in the development of obesity.

    “Unhealthy dietary patterns, characterized by high intakes of refined, high-glycemic load carbohydrates and low intakes of dietary fiber, play a crucial role in the development of obesity (4).”

    From Prebiotic soda lowers postprandial glucose compared to traditional soda pop: a randomized controlled trial (2025) · cites this paper as [4]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 180

  1. [3]Forse RA Betancourt-Garcia MM Kissee MC. Epidemiology and discrimination in obesity. In: The ASMBS textbook of bariatric surgery Springer (2020). p. 3– 14.
  2. [4]Smith KB Smith MS. Obesity statistics. Primary care: Clinics office Pract (2016) 43(1): 121–35. doi: 10.1016/j.pop.2015.10.001 26896205 · DOI
  3. [5]James PT Leach R Kalamara E Shayeghi M. The worldwide obesity epidemic. Obes Res (2001) 9(S11): 228S–33S. doi: 10.1038/oby.2001.123 11707546 · DOI · Paper page
  4. [6]Smith SR Weissman NJ Anderson CM Sanchez M Chuang E Stubbe S. Multicenter, placebo-controlled trial of lorcaserin for weight management. New Engl J Med (2010) 363(3): 245–56. doi: 10.1056/NEJMoa0909809 20647200 · DOI · Paper page
  5. [8]Zhang Y Yu L Cai W Fan S Feng L Ji G. Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice. Sci Rep (2014) 4(1): 7375. doi: 10.1038/srep07375 25487878 PMC4260220 · DOI
  6. [9]Miranda J Vázquez-Polo M Pérez-Junkera G Fernández-Gil MDP Bustamante MÁ. Navarro V. FODMAP intake in Spanish population: open approach for risk assessment. Int J Environ Res Public Health (2020) 17(16): 5882. doi: 10.3390/ijerph17165882 32823689 PMC7459496 · DOI
  7. [10]Pollex RL Hanley AJ Zinman B Harris SB Khan HM Hegele RA. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis (2006) 184(1): 121–9. doi: 10.1016/j.atherosclerosis.2005.03.024 15869758 · DOI
  8. [11]Kumar M Guleria S Chawla P Khan A Modi VK Kumar N. Anti-obesity efficacy of the selected high altitude Himalayan herbs: In vitro studies. J Food Sci Technol (2020) 57: 3081–90. doi: 10.1007/s13197-020-04341-5 PMC7316926 32624610 · DOI
  9. [12]Ogden CL Carroll MD Curtin LR McDowell MA Tabak CJ Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. Jama (2006) 295(13): 1549–55. doi: 10.1001/jama.295.13.1549 16595758 · DOI · Paper page
  10. [13]Pimpley V Patil S Srinivasan K Desai N Murthy PS. The chemistry of chlorogenic acid from green coffee and its role in attenuation of obesity and diabetes. Preparative Biochem Biotechnol (2020) 50(10): 969–78. doi: 10.1080/10826068.2020.1786699 32633686 · DOI
  11. [14]Mishra D Naorem K Saraswathy KN. Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiometabolic risk factors: A study among Bhil tribal population from two environmental settings. Biochem Genet (2018) 56: 295– 314. doi: 10.1007/s10528-018-9845-x 29435690 · DOI
  12. [15]Kandpal V Sachdeva MP Saraswathy KN. An assessment study of CVD related risk factors in a tribal population of India. BMC Public Health (2016) 16: 1– 8. doi: 10.1186/s12889-016-3106-x 27225632 PMC4880982 · DOI
  13. [16]Cameron AJ Zimmet PZ Dunstan DW Dalton M Shaw JE Welborn TA. Overweight and obesity in Australia: the 1999–2000 Australian diabetes, obesity and lifestyle study (AusDiab). Med J Aust (2003) 178(9): 427–32. doi: 10.5694/j.1326-5377.2003.tb05283.x 12720507 · DOI
  14. [17]Ruxton CHS. Nutritional implications of obesity and dieting. Nutr Bull (2011) 36(2): 199– 211. doi: 10.1111/j.1467-3010.2011.01890.x · DOI
  15. [18]Mendez MA Popkin BM Buckland G Schroder H Amiano P Barricarte A. Alternative methods of accounting for underreporting and overreporting when measuring dietary intake-obesity relations. Am J Epidemiol (2011) 173(4): 448–58. doi: 10.1093/aje/kwq380 PMC3139974 21242302 · DOI
  16. [19]Paradis AM Godin G Pérusse L Vohl MC. Associations between dietary patterns and obesity phenotypes. Int J Obes (2009) 33(12): 1419–26. doi: 10.1038/ijo.2009.179 19736556 · DOI
  17. [20]Abate N. Insulin resistance and obesity: the role of fat distribution pattern. Diabetes Care (1996) 19(3): 292–4. doi: 10.2337/diacare.19.3.292 8742585 · DOI
  18. [21]Kumar M Kaushik D Kaur J Proestos C Oz F Oz E. A critical review on obesity: Herbal approach, bioactive compounds, and their mechanism. Appl Sci (2022) 12(16): 8342. doi: 10.3390/app12168342 · DOI
  19. [22]Najjar SM Perdomo G. Hepatic insulin clearance: mechanism and physiology. Physiology (2019) 34(3): 198– 215. doi: 10.1152/physiol.00048.2018 30968756 PMC6734066 · DOI
  20. [23]Kahn CR. Role of insulin receptors in insulin-resistant states. Metabolism (1980) 29(5): 455–66. doi: 10.1016/0026-0495(80)90171-7 6990180 · DOI
  21. [24]Moller DE Flier JS. Insulin resistance—mechanisms, syndromes, and implications. New Engl J Med (1991) 325(13): 938–48. doi: 10.1056/NEJM199109263251307 1881419 · DOI
  22. [25]Lin X Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (2021) 12: 706978. doi: 10.3389/fendo.2021.706978 PMC8450866 34552557 · DOI
  23. [26]Cheng Z Zhang L Yang L Chu H. The critical role of gut microbiota in obesity. Front Endocrinol (2022) 13. doi: 10.3389/fendo.2022.1025706 PMC9630587 36339448 · DOI · Paper page
  24. [27]Clarke G Stilling RM Kennedy PJ Stanton C Cryan JF Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol (2014) 28(8): 1221–38. doi: 10.1210/me.2014-1108 PMC5414803 24892638 · DOI · Paper page
  25. [28]Jia Q Xie Y Lu C Zhang A Lu Y Lv S. Endocrine organs of cardiovascular diseases: Gut microbiota. J Cell Mol Med (2019) 23(4): 2314–23. doi: 10.1111/jcmm.14164 PMC6433674 30688023 · DOI
  26. [29]Chen Y Zhou J Wang L. Role and mechanism of gut microbiota in human disease. Front Cell infection Microbiol (2021) 86. doi: 10.3389/fcimb.2021.625913 PMC8010197 33816335 · DOI
  27. [30]Kaaks R Lukanova A Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev (2002) 11(12): 1531–43. 12496040
  28. [31]Philippe G. Gut microbiota and obesity. Cel Mol Life Sci (2016) 73(1): 147–62. doi: 10.1007/s00018-015-2061-5 PMC11108539 26459447 · DOI
  29. [32]Thursby E Juge N. Introduction to the human gut microbiota. Biochem J (2017) 474(11): 1823–36. doi: 10.1042/BCJ20160510 PMC5433529 28512250 · DOI · Paper page
  30. [33]Fan Y Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol (2021) 19(1): 55– 71. doi: 10.1038/s41579-020-0433-9 32887946 · DOI · Paper page
  31. [34]Li C Zhou K Xiao N Peng M Tan Z. The effect of qiweibaizhu powder crude polysaccharide on antibiotic-associated diarrhea mice is associated with restoring intestinal mucosal bacteria. Front Nutr (2022) 9. doi: 10.3389/fnut.2022.952647 PMC9305308 35873450 · DOI
  32. [35]Qiao B Li X Peng M Hui H Tan Z. Alteration of intestinal mucosal microbiota in mice with Chinese dampness-heat syndrom diarrhea by improper diet combined with high temperature and humidity environments. Front Cell Infection Microbiol (2023) 12: 1944. doi: 10.3389/fcimb.2022.1096202 PMC9845886 36683693 · DOI
  33. [36]Yang RZ Lee MJ Hu H Pray J Wu HB Hansen BC. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J physiology-endocrinol Metab (2006) 290(6): E1253–61. doi: 10.1152/ajpendo.00572.2004 16531507 · DOI · Paper page
  34. [37]He L Long C Liu Y Guo Y Xiao N Tan Z. Effects of Debaryomyces hansenii treatment on intestinal microorganisms in mice with antibiotics-induced diarrhea. 3 Biotech (2017) 7: 1– 7. doi: 10.1007/s13205-017-0953-9 PMC5612875 28955644 · DOI
  35. [38]Long C Liu Y He L Tan Q Yu Z Xiao N. Bacterial lactase genes diversity in intestinal mucosa of mice with dysbacterial diarrhea induced by antibiotics. 3 Biotech (2018) 8: 1– 9. doi: 10.1007/s13205-018-1191-5 PMC5847641 29556430 · DOI
  36. [39]Xie G Tan K Peng M Long C Li D Tan Z. Bacterial diversity in intestinal mucosa of antibiotic-associated diarrhea mice. 3 Biotech (2019) 9: 1– 8. doi: 10.1007/s13205-019-1967-2 PMC6842370 31763122 · DOI
  37. [40]Zhou K Peng M Deng N Tan Z Xiao N. Lactase bacteria in intestinal mucosa are associated with diarrhea caused by high-fat and high-protein diet. BMC Microbiol (2022) 22(1): 226. doi: 10.1186/s12866-022-02647-2 36171559 PMC9516839 · DOI
  38. [41]Liu R Wakabayashi G Kim HJ Choi GH Yiengpruksawan A Fong Y. International consensus statement on robotic hepatectomy surgery in 2018. World J Gastroenterol (2019) 25(12): 1432–530. doi: 10.3748/wjg.v25.i12.1432 PMC6441912 30948907 · DOI
  39. [42]Li X Deng N Zheng T Qiao B Peng M Xiao N. Importance of Dendrobium officinale in improving the adverse effects of high-fat diet on mice associated with intestinal contents microbiota. Front Nutr (2022) 9: 957334–4. doi: 10.3389/fnut.2022.957334 PMC9365999 35967811 · DOI
  40. [43]Wu Y Zhang C Shao H Luo H Tan Z. Characteristics of intestinal microbiota and enzyme activities in mice fed with lily bulb. 3 Biotech (2021) 11: 1– 8. doi: 10.1007/s13205-020-02597-4 PMC7778670 33442516 · DOI
  41. [44]Shao H Zhang C Wang C Tan Z. Intestinal mucosal bacterial diversity of antibiotic-associated diarrhea (AAD) mice treated with Debaryomyces hansenii and Qiweibaizhu powder. 3 Biotech (2020) 10: 1– 11. doi: 10.1007/s13205-020-02383-2 32832342 PMC7429618 · DOI
  42. [45]Yuan Z Zhang C Peng X Shu L Long C Tan Z. Intestinal microbiota characteristics of mice treated with Folium senna decoction gavage combined with restraint and tail pinch stress. 3 Biotech (2020) 10: 1– 11. doi: 10.1007/s13205-020-02172-x 32231961 PMC7101465 · DOI
  43. [46]Zhang C Shao H Peng X Liu T Tan Z. Microbiotal characteristics colonized in intestinal mucosa of mice with diarrhoea and repeated stress. 3 Biotech (2020) 10: 1– 12. doi: 10.1007/s13205-020-02368-1 32832332 PMC7399726 · DOI
  44. [47]Long C Liu Y He L Yu R Li D Tan Z. Bacterial lactase genes diversity in intestinal mucosa of dysbacterial diarrhea mice treated with Qiweibaizhu powder. 3 Biotech (2018) 8: 1– 8. doi: 10.1007/s13205-018-1460-3 PMC6160371 30280074 · DOI
  45. [48]Xie G Deng N Zheng T Peng X Zhang S Tan Z. Total glycosides contribute to the anti-diarrheal effects of Qiwei Baizhu Powder via regulating gut microbiota and bile acids. Front Cell Infection Microbiol (2022) 12. doi: 10.3389/fcimb.2022.945263 PMC9444044 36072221 · DOI
  46. [49]Li X Zhang C Tan Z Yuan J. Network pharmacology-based analysis of gegenqinlian decoction regulating intestinal microbial activity for the treatment of diarrhea. Evidence-Based Complementary Altern Med (2021) 2021: 1–13. doi: 10.1155/2021/5520015 PMC8331269 34354757 · DOI
  47. [50]Turnbaugh PJ Hamady M Yatsunenko T Cantarel BL Duncan A Ley RE. A core gut microbiome in obese and lean twins. Nature (2009) 457: 480–4. doi: 10.1038/nature07540 PMC2677729 19043404 · DOI · Paper page
  48. [51]Wang P Gao J Ke W Wang J Li D Liu R. Resveratrol reduces obesity in high-fat diet-fed mice via modulating the composition and metabolic function of the gut microbiota. Free Radical Biol Med (2020) 156: 83– 98. doi: 10.1016/j.freeradbiomed.2020.04.013 32305646 · DOI
  49. [52]Solano-Aguilar G Shea-Donohue T Madden KB Quinones A Beshah E Lakshman S. Bifidobacterium animalis subspecies lactis modulates the local immune response and glucose uptake in the small intestine of juvenile pigs infected with the parasitic nematode Ascaris suum. Gut Microbes (2018) 9(5): 422–36. doi: 10.1080/19490976.2018.1460014 PMC6219643 30024817 · DOI
  50. [53]Muscogiuri G Cantone E Cassarano S Tuccinardi D Barrea L Savastano S. Gut microbiota: a new path to treat obesity. Int J Obes Suppl (2019) 9(1): 10–9. doi: 10.1038/s41367-019-0011-7 PMC6683132 31391921 · DOI
  51. [54]Wostmann BS Larkin C Moriarty A Bruckner-Kardoss E. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci (1983) 33(1): 46– 50. 6834773
  52. [55]Backing F Ding H Wang T Hooper LV Koh GY Nagy A. Gutmikrobioten som en miljøfaktor som regulerer fettlagring. Proc Natl Acad Sci USA (2004) 101: 15718–23. doi: 10.1073/pnas.0407076101 PMC524219 15505215 · DOI · Paper page
  53. [56]O'Neil PM Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomized, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (2018) 392(10148): 637–49. doi: 10.1016/S0140-6736(18)31773-2 30122305 · DOI · Paper page
  54. [57]Khera R Murad MH Chandar AK Dulai PS Wang Z Prokop LJ. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama (2016) 315(22): 2424–34. doi: 10.1001/jama.2016.7602 PMC5617638 27299618 · DOI · Paper page
  55. [58]Nissen SE Wolski KE Prcela L Wadden T Buse JB Bakris G. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. Jama (2016) 315(10): 990– 1004. doi: 10.1001/jama.2016.1558 26954408 · DOI · Paper page
  56. [60]Zhang CH Sheng JQ Xie WH Luo XQ Xue YN Xu GL. Mechanism and basis of traditional Chinese medicine against obesity: prevention and treatment strategies. Front Pharmacol (2021) 12: 615895. doi: 10.3389/fphar.2021.615895 33762940 PMC7982543 · DOI
  57. [61]Aaseth J Ellefsen S Alehagen U Sundfør TM Alexander J. Diets and drugs for weight loss and health in obesity–An update. Biomed Pharmacother (2021) 140: 111789. doi: 10.1016/j.biopha.2021.111789 34082399 · DOI
  58. [62]Wang L Yu CC Li J Tian Q Du YJ. Mechanism of action of acupuncture in obesity: a perspective from the hypothalamus. Front Endocrinol (2021) 12: 632324. doi: 10.3389/fendo.2021.632324 PMC8050351 33868169 · DOI
  59. [63]de Souza Batista CM Yang RZ Lee MJ Glynn NM Yu DZ Pray J. Omentin plasma levels and gene expression are decreased in obesity. Diabetes (2007) 56(6): 1655–61. doi: 10.2337/db06-1506 17329619 · DOI
  60. [64]Adrian TE Ferri GL Bacarese-Hamilton AJ Fuessl HS Polak JM Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology (1985) 89(5): 1070–7. doi: 10.1016/0016-5085(85)90211-2 3840109 · DOI
  61. [65]Fan Q Xu F Liang B Zou X. The anti-obesity effect of traditional Chinese medicine on lipid metabolism. Front Pharmacol (2021) 12: 696603. doi: 10.3389/fphar.2021.696603 34234682 PMC8255923 · DOI
  62. [66]Krentz AJ Fujioka K Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab (2016) 18(6): 558–70. doi: 10.1111/dom.12657 26936802 · DOI
  63. [67]Le Chatelier E Nielsen T Qin J Prifti E Hildebrand F Falony G. Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 500(7464): 541–6. doi: 10.1038/nature12506 23985870 · DOI · Paper page
  64. [69]Batterham RL Cowley MA Small CJ Herzog H Cohen MA Dakin CL. Gut hormone PYY3-36 physiologically inhibits food intake. Nature (2002) 418(6898): 650–4. doi: 10.1038/nature00887 12167864 · DOI · Paper page
  65. [70]Karra E Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol (2010) 316(2): 120–8. doi: 10.1016/j.mce.2009.06.010 19563862 · DOI
  66. [71]Paz-Filho G Mastronardi CA Licinio J. Leptin treatment: facts and expectations. Metabolism (2015) 64(1): 146–56. doi: 10.1016/j.metabol.2014.07.014 25156686 · DOI
  67. [72]Heymsfield SB Greenberg AS Fujioka K Dixon RM Kushner R Hunt T. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Jama (1999) 282(16): 1568–75. doi: 10.1001/jama.282.16.1568 10546697 · DOI · Paper page
  68. [73]Piché ME Tchernof A Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res (2020) 126(11): 1477–500. doi: 10.1161/CIRCRESAHA.120.316101 32437302 · DOI
  69. [74]Vallianou N Stratigou T Christodoulatos GS Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: current evidence and perspectives. Curr Obes Rep (2019) 8: 317–32. doi: 10.1007/s13679-019-00352-2 31175629 · DOI
  70. [75]Moszak M Szulińska M Bogdański P. You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review. Nutrients (2020) 12(4): 1096. doi: 10.3390/nu12041096 32326604 PMC7230850 · DOI · Paper page
  71. [76]Merra G Noce A Marrone G Cintoni M Tarsitano MG Capacci A. Influence of mediterranean diet on human gut microbiota. Nutrients (2020) 13: 7. doi: 10.3390/nu13010007 33375042 PMC7822000 · DOI · Paper page
  72. [77]Qiao B Li X Zheng T Tan Z. Different effects of lard and vegetable blend oil on intestinal microorganisms, enzyme activity and blood routine in mice. J Oleo Sci (2022) 71(2): 301–10. doi: 10.5650/jos.ess21247 35034939 · DOI
  73. [78]Turnbaugh P Ley R Mahowald M Magrini V Mardis E Gordon J. En fedme-assosiert tarmmikrobiom med økt kapasitet for energihøsting. Naturen (2006) 444(7122): 1027–31. doi: 10.1038/nature05414 17183312 · DOI · Paper page
  74. [79]Meijnikman AS Aydin O Prodan A Tremaroli V Herrema H Levin E. Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects. J Internal Med (2020) 288(6): 699– 710. doi: 10.1111/joim.13137 32633011 · DOI
  75. [80]Kobyliak N Virchenko O Falalyeyeva T. Pathophysiological role of host microbiota in the development of obesity. Nutr J (2015) 15: 1– 12. doi: 10.1186/s12937-016-0166-9 PMC4841968 27105827 · DOI
  76. [81]Petersen C Bell R Klag KA Lee SH Soto R Ghazaryan A. T cell–mediated regulation of the microbiota protects against obesity. Science (2019) 365(6451): eaat9351. doi: 10.1126/science.aat9351 31346040 PMC7294966 · DOI · Paper page
  77. [82]Everard A Belzer C Geurts L Ouwerkerk JP Druart C Bindels LB. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci (2013) 110(22): 9066–71. doi: 10.1073/pnas.1219451110 PMC3670398 23671105 · DOI · Paper page
  78. [83]Wu D Wang H Xie L Hu F. Cross-talk between gut microbiota and adipose tissues in obesity and related metabolic diseases. Front Endocrinol (2022) 13. doi: 10.3389/fendo.2022.908868 PMC9294175 35865314 · DOI
  79. [84]Koh A De Vadder F Kovatcheva-Datchary P Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell (2016) 165(6): 1332–45. doi: 10.1016/j.cell.2016.05.041 27259147 · DOI · Paper page
  80. [85]Canfora EE Meex RC Venema K Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol (2019) 15(5): 261–73. doi: 10.1038/s41574-019-0156-z 30670819 · DOI · Paper page
  81. [86]Li C Xiao N Deng N Li D Tan Z Peng M. Dose of sucrose affects the efficacy of Qiweibaizhu powder on antibiotic-associated diarrhea: association with intestinal mucosal microbiota, short-chain fatty acids, IL-17 and MUC2. Front Microbiol (2023) 14: 43. doi: 10.3389/fmicb.2023.1108398 PMC9893413 36744095 · DOI
  82. [87]Zhang L Liu C Jiang Q Yin Y. Butyrate in energy metabolism: there is still more to learn. Trends Endocrinol Metab (2021) 32(3): 159–69. doi: 10.1016/j.tem.2020.12.003 33461886 · DOI
  83. [88]Cani PD Hul MV Lefort C Depommier C Rastelli M Everard A. Microbial regulation of organismal energy homeostasis. Nature metabolism (2019) 1(1): 34–46. doi: 10.1038/s42255-018-0017-4 32694818 · DOI · Paper page
  84. [90]Fogteloo AJ Pijl H Frölich M McCamish M Meinders AE. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes Nutr Metab (2003) 16(2): 109–14. 12846450
  85. [92]Paglialunga S Schrauwen P Roy C Moonen-Kornips E Lu H Hesselink MK. Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol (2007) 194(2): 293– 304. doi: 10.1677/JOE-07-0205 17641279 · DOI
  86. [93]Murray I Havel PJ Sniderman AD Cianflone K. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology (2000) 141(3): 1041–9. doi: 10.1210/endo.141.3.7364 10698180 · DOI
  87. [94]Li N Guo Y Gong Y Zhang Y Fan W Yao K. The anti-inflammatory actions and mechanisms of acupuncture from acupoint to target organs via neuro-immune regulation. J Inflammation Res (2021) 14: 7191. doi: 10.2147/JIR.S341581 PMC8710088 34992414 · DOI
  88. [95]Li X Yin Z Ling F Zheng Q Li X Qi W. The application of acupuncture in cardiopathy: A bibliometric analysis based on Web of Science across ten recent years. Front Cardiovasc Med (2022) 9: 920491. doi: 10.3389/fcvm.2022.920491 36148057 PMC9485815 · DOI
  89. [96]Chithanathan K Somelar K Jürgenson M Žarkovskaja T Periyasamy K Yan L. Enhanced cognition and neurogenesis in miR-146b deficient mice. Cells (2022) 11(13): 2002. doi: 10.3390/cells11132002 35805086 PMC9265316 · DOI
  90. [97]Cordido F Penalva A Dieguez C Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab (1993) 76(4): 819–23. doi: 10.1210/jcem.76.4.8473389 8473389 · DOI
  91. [98]Alvarez-Castro P Isidro ML Garcia-Buela J Leal-Cerro A Broglio F Tassone F. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients. Clin Endocrinol (2004) 61(2): 250–5. doi: 10.1111/j.1365-2265.2004.02092.x 15272922 · DOI
  92. [99]Kojima M Hosoda H Matsuo H Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab (2001) 12(3): 118–22. doi: 10.1016/S1043-2760(00)00362-3 11306336 · DOI
  93. [100]Tschop M Weyer C Tataranni PA Devanarayan V Ravussin E Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50(4): 707–9. doi: 10.2337/diabetes.50.4.707 11289032 · DOI
  94. [101]Otto B Cuntz U Fruehauf EA Wawarta R Folwaczny C Riepl RL. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol (2001) 145(5): R5–9. doi: 10.1530/EJE-1450669 11720888 · DOI
  95. [102]Tuzcu Z Orhan C Sahin N Juturu V Sahin K. Cinnamon polyphenol extract inhibits hyperlipidemia and inflammation by modulation of transcription factors in high-fat diet-fed rats. Oxid Med Cell Longevity (2017) 1583098. doi: 10.1155/2017/1583098 PMC5370473 28396714 · DOI
  96. [103]Ukkola O. Ghrelin and insulin metabolism. Eur J Clin Invest (2003) 33(3): 183–5. doi: 10.1046/j.1365-2362.2003.01112.x 12641533 · DOI
  97. [105]Cummings DE Frayo RS Marmonier C Aubert R Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time-and food-related cues. Am J Physiology-Endocrinol Metab (2004) 287(2): E297–304. doi: 10.1152/ajpendo.00582.2003 15039149 · DOI
  98. [107]Twig G Yaniv G Levine H Leiba A Goldberger N Derazne E. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. New Engl J Med (2016) 374(25): 2430–40. doi: 10.1056/NEJMoa1503840 27074389 · DOI · Paper page
  99. [108]Belanger MJ Hill MA Angelidi AM Dalamaga M Sowers JR Mantzoros CS. Covid-19 and disparities in nutrition and obesity. New Engl J Med (2020) 383(11): e69. doi: 10.1056/NEJMp2021264 32668105 · DOI
  100. [109]Arnold M Pandeya N Byrnes G Renehan AG Stevens GA Ezzati M. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol (2015) 16(1): 36– 46. doi: 10.1016/S1470-2045(14)71123-4 25467404 PMC4314462 · DOI
  101. [110]Bray MS Loos RJ McCaffery JM Ling C Franks PW Weinstock GM. & Conference Working Group. NIH working group report—using genomic information to guide weight management: From universal to precision treatment. Obesity (Silver Spring, Md.) (2016) 24(1): 14. doi: 10.1002/oby.21381 26692578 PMC4689320 · DOI · Paper page
  102. [111]Wilding JP Batterham RL Calanna S Davies M Van Gaal LF Lingvay I. Once-weekly semaglutide in adults with overweight or obesity. New Engl J Med (2021) 384(11): 989–1002. doi: 10.1056/NEJMoa2032183 33567185 · DOI · Paper page
  103. [112]Tak YJ Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Men's Health (2021) 39(2): 208. doi: 10.5534/wjmh.200010 32202085 PMC7994651 · DOI
  104. [113]Bray GA Frühbeck G Ryan DH Wilding JP. Management of obesity. Lancet (2016) 387(10031): 1947–56. doi: 10.1016/S0140-6736(16)00271-3 26868660 · DOI · Paper page
  105. [117]Stefan N Häring HU Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol (2018) 6(3): 249–58. doi: 10.1016/S2213-8587(17)30292-9 28919065 · DOI
  106. [118]Adriaenssens AE Gribble FM Reimann F. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system. Peptides (2020) 125: 170194. doi: 10.1016/j.peptides.2019.170194 31697967 · DOI
  107. [120]Tirosh A Calay ES Tuncman G Claiborn KC Inouye KE Eguchi K. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Trans Med (2019) 11(489): eaav0120. doi: 10.1126/scitranslmed.aav0120 31019023 · DOI
  108. [121]Engevik MA Luck B Visuthranukul C Ihekweazu FD Engevik AC Shi Z. Human-derived Bifidobacterium dentium modulates the mammalian serotonergic system and gut–brain axis. Cell Mol Gastroenterol Hepatol (2021) 11(1): 221–48. doi: 10.1016/j.jcmgh.2020.08.002 PMC7683275 32795610 · DOI · Paper page
  109. [122]Generoso JS Giridharan VV Lee J Macedo D Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry (2020) 43: 293– 305. doi: 10.1590/1516-4446-2020-0987 PMC8136391 32667590 · DOI
  110. [123]Adams TD Davidson LE Litwin SE Kim J Kolotkin RL Nanjee MN. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med (2017) 377: 1143–55. doi: 10.1056/NEJMoa1700459 PMC5737957 28930514 · DOI · Paper page
  111. [124]Hauner H Hastreiter L Werdier D Chen-Stute A Scholze J Blüher M. Efficacy and safety of cathine (nor-pseudoephedrine) in the treatment of obesity: a randomized dose-finding study. Obes Facts (2017) 10(4): 407–19. doi: 10.1159/000478098 PMC5644935 28873376 · DOI
  112. [125]Lucchetta RC Riveros BS Pontarolo R Radominski RB Otuki MF Fernandez-Llimos F. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics (2017) 72: 317–24. doi: 10.6061/clinics/2017(05)10 PMC5439101 28591345 · DOI
  113. [126]Müller TD Clemmensen C Finan B DiMarchi RD Tschöp MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev (2018) 70(4): 712–46. doi: 10.1124/pr.117.014803 30087160 · DOI · Paper page
  114. [127]Davies M Færch L Jeppesen OK Pakseresht A Pedersen SD Perreault L. Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (2021) 397(10278): 971–84. doi: 10.1016/S0140-6736(21)00213-0 33667417 · DOI · Paper page
  115. [128]Rubino D Abrahamsson N Davies M Hesse D Greenway FL Jensen C. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama (2021) 325(14): 1414–25. doi: 10.1001/jama.2021.3224 PMC7988425 33755728 · DOI · Paper page
  116. [129]Wilding JP Calanna S Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. Reply. New Engl J Med (2021) 385(1): e4–4. doi: 10.1056/NEJMoa2032183 34192450 · DOI · Paper page
  117. [130]Torres-Fuentes C Schellekens H Dinan TG Cryan JF. The microbiota–gut–brain axis in obesity. Lancet Gastroenterol Hepatol (2017) 2(10): 747–56. doi: 10.1016/S2468-1253(17)30147-4 28844808 · DOI
  118. [131]Oduro-Donkor D Turner MC Farnaud S Renshaw D Kyrou I Hanson P. Modification of fecal microbiota as a mediator of effective weight loss and metabolic benefits following bariatric surgery. Expert Rev Endocrinol Metab (2020) 15(5): 363–73. doi: 10.1080/17446651.2020.1801412 32840125 · DOI · Paper page
  119. [132]Cunningham AL Stephens JW Harris DA. A review on gut microbiota: a central factor in the pathophysiology of obesity. Lipids Health Dis (2021) 20(1): 1– 13. doi: 10.1186/s12944-021-01491-z 34233682 PMC8262044 · DOI
  120. [133]Naraoka Y Yamaguchi T Hu A Akimoto K Kobayashi H. Short chain fatty acids upregulate adipokine production in type 2 diabetes-derived human adipocytes. Acta Endocrinol (Bucharest) (2018) 14(3): 287. doi: 10.4183/aeb.2018.287 PMC6525780 31149273 · DOI
  121. [134]Kusaczuk M. Tauroursodeoxycholate—bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cells (2019) 8(12): 1471. doi: 10.3390/cells8121471 31757001 PMC6952947 · DOI
  122. [135]Vettorazzi JF Kurauti MA Soares GM Borck PC Ferreira SM Branco RCS. Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice. Sci Rep (2017) 7(1): 14876. doi: 10.1038/s41598-017-13974-0 29093479 PMC5665899 · DOI
  123. [136]Zangerolamo L Vettorazzi JF Solon C Bronczek GA Engel DF Kurauti MA. The bile acid TUDCA improves glucose metabolism in streptozotocin-induced Alzheimer's disease mice model. Mol Cell Endocrinol (2021) 521: 111116. doi: 10.1016/j.mce.2020.111116 33321116 · DOI
  124. [138]Pereira MJ Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs (2019) 79(3): 219–30. doi: 10.1007/s40265-019-1057-0 PMC6394798 30701480 · DOI · Paper page
  125. [139]Davis LK Yu D Keenan CL Gamazon ER Konkashbaev AI Derks EM. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PloS Genet (2013) 9(10): e1003864. doi: 10.1371/journal.pgen.1003864 24204291 PMC3812053 · DOI
  126. [141]Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol (2021) 9(7): 418. doi: 10.1016/S2213-8587(21)00145-5 34087168 · DOI
  127. [142]Matthias B. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol (2019) 15(5): 288–98. doi: 10.1038/s41574-019-0176-8 30814686 · DOI · Paper page
  128. [144]Ugur K Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol (2019) 2019: 2521096. doi: 10.1155/2019/2521096 31049060 PMC6458951 · DOI
  129. [145]Brown LM Gent L Davis K Clegg DJ. Metabolic impact of sex hormones on obesity. Brain Res (2010) 1350: 77– 85. doi: 10.1016/j.brainres.2010.04.056 20441773 PMC2924463 · DOI
  130. [146]Sparano JA Wang M Zhao F Stearns V Martino S Ligibel JA. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (2012) 118(23): 5937–46. doi: 10.1002/cncr.27527 PMC3586227 22926690 · DOI
  131. [147]Rothermel J Lass N Barth A Reinehr T. Link between omentin-1, obesity and insulin resistance in children: Findings from a longitudinal intervention study. Pediatr Obes (2020) 15(5): e12605. doi: 10.1111/ijpo.12605 31840425 · DOI
  132. [148]Wroblewski E Swidnicka-Siergiejko A Hady HR Luba M Konopko M Kurek K. Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies. Cytokine (2016) 77: 56– 62. doi: 10.1016/j.cyto.2015.10.013 26539806 · DOI
  133. [149]Berstein LM Ievleva AG Mukhina MS Vasiliev DA Poroshina TE. Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes. Voprosy Onkologii (2016) 63(2): 79– 84. 30444337
  134. [150]Amjad S Baig M Zahid N Tariq S Rehman R. Association between leptin, obesity, hormonal interplay and male infertility. Andrologia (2019) 51(1): e13147. doi: 10.1111/and.13147 30255520 · DOI
  135. [151]Salas-Huetos A Maghsoumi-Norouzabad L James ER Carrell DT Aston KI Jenkins TG. Male adiposity, sperm parameters and reproductive hormones: An updated systematic review and collaborative meta-analysis. Obes Rev (2021) 22(1): e13082. doi: 10.1111/obr.13082 32705766 · DOI
  136. [152]Almabhouh FA Md Mokhtar AH Malik IA Aziz NAAA Durairajanayagam D Singh HJ. Leptin and reproductive dysfunction in obese men. Andrologia (2020) 52(1): e13433. doi: 10.1111/and.13433 31773771 · DOI
  137. [153]Dornbush S Aeddula NR. Physiology. In: Leptin. Treasure Island, FL, USA: StatPearls Publishing (2021). 30725723
  138. [154]Leisegang K Sengupta P Agarwal A Henkel R. Obesity and male infertility: Mechanisms and management. Andrologia (2021) 53(1): e13617. doi: 10.1111/and.13617 32399992 · DOI
  139. [155]Cianflone K Xia Z Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta (BBA)-Biomembranes (2003) 1609(2): 127–43. doi: 10.1016/S0005-2736(02)00686-7 12543373 · DOI
  140. [156]Goralski KB McCarthy TC Hanniman EA Zabel BA Butcher EC Parlee SD. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem (2007) 282(38): 28175–88. doi: 10.1074/jbc.M700793200 17635925 · DOI
  141. [157]Fisette A Lapointe M Cianflone K. Obesity-inducing diet promotes acylation stimulating protein resistance. Biochem Biophys Res Commun (2013) 437(3): 403–7. doi: 10.1016/j.bbrc.2013.06.090 23831465 · DOI
  142. [158]Bays HE Jones PH Jacobson TA Cohen DE Orringer CE Kothari S. Lipids and bariatric procedures part 1 of 2: scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and obesity medicine association: FULL REPORT. J Clin lipidology (2016) 10(1): 33– 57. doi: 10.1016/j.jacl.2015.12.002 26892120 · DOI
  143. [159]Ursini F Abenavoli L. The emerging role of complement C3 as a biomarker of insulin resistance and cardiometabolic diseases: preclinical and clinical evidence. Rev Recent Clin trials (2018) 13(1): 61–8. doi: 10.2174/1574887112666171128134552 29189176 · DOI
  144. [160]Sniderman AD Cianflone K Summers L Fielding B Frayn K. The acylation-stimulating protein pathway and regulation of postprandial metabolism. Proc Nutr Soc (1997) 56(2): 703–12. doi: 10.1079/PNS19970070 9264120 · DOI
  145. [161]Mishra S Gupta V Mishra S Gupta V Mahdi AA Sachan R. An increase level of acylation stimulating protein is correlated with metabolic risk markers in North Indian obese women. Diabetes Metab Syndrome: Clin Res Rev (2017) 11: S797–801. doi: 10.1016/j.dsx.2017.06.001 28610914 · DOI
  146. [162]Corvillo F Akinci B. An overview of lipodystrophy and the role of the complement system. Mol Immunol (2019) 112: 223–32. doi: 10.1016/j.molimm.2019.05.011 31177059 · DOI
  147. [163]Bays HE Toth PP Kris-Etherton PM Abate N Aronne LJ Brown WV. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin lipidology (2013) 7(4): 304–83. doi: 10.1016/j.jacl.2013.04.001 23890517 · DOI · Paper page
  148. [164]Phillips CM Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab (2013) 98(10): E1610–9. doi: 10.1210/jc.2013-2038 23979951 · DOI
  149. [165]Hansen D Dendale P Beelen M Jonkers RA Mullens A Corluy L. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol (2010) 109: 397– 404. doi: 10.1007/s00421-010-1362-5 20131064 PMC2874484 · DOI
  150. [166]Wren AM Seal LJ Cohen MA Brynes AE Frost GS Murphy KG. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 86: 5992. doi: 10.1210/jcem.86.12.8111 11739476 · DOI · Paper page
  151. [168]Woźniak D Cichy W Przysławski J Drzymała-Czyż S. The role of microbiota and enteroendocrine cells in maintaining homeostasis in the human digestive tract. Adv Med Sci (2021) 66(2): 284–92. doi: 10.1016/j.advms.2021.05.003 34098509 · DOI
  152. [169]Wawrzyniak N Skrypnik K Suliburska J. Dietary supplements in therapy to support weight reduction in obese patients. Acta Scientiarum Polonorum Technol Alimentaria (2022) 21(1): 67– 80. doi: 10.17306/J.AFS.2022.1010 35174689 · DOI
  153. [170]Huang M Cople-Rodrigues CDS Waitzberg DL Rocha IMGD Curioni CC. Changes in the gut microbiota after the use of herbal medicines in overweight and obese individuals: A systematic review. Nutrients (2023) 15(9): 2203. doi: 10.3390/nu15092203 37432344 PMC10181072 · DOI
  154. [171]Łagowska K Drzymała-Czyż S. A low glycemic index, energy-restricted diet but not Lactobacillus rhamnosus supplementation changes fecal short-chain fatty acid and serum lipid concentrations in women with overweight or obesity and polycystic ovary syndrome. Eur Rev Med Pharmacol Sci (2022) 26(3): 917–26. doi: 10.26355/eurrev_202202_28001 35179758 · DOI
  155. [172]Dixon JB Le Roux CW Rubino F Zimmet P. Bariatric surgery for type 2 diabetes. Lancet (2012) 379(9833): 2300–11. doi: 10.1016/S0140-6736(12)60401-2 22683132 · DOI
  156. [173]Schauer PR Bhatt DL Kirwan JP Wolski K Aminian A Brethauer SA. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med (2017) 376: 641–51. doi: 10.1056/NEJMoa1600869 PMC5451258 28199805 · DOI · Paper page
  157. [174]Vetter ML Cardillo S Rickels MR Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Internal Med (2009) 150(2): 94– 103. doi: 10.7326/0003-4819-150-2-200901200-00007 19153412 · DOI
  158. [176]Schauer PR Kashyap SR Wolski K Brethauer SA Kirwan JP Pothier CE. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. New Engl J Med (2012) 366(17): 1567–76. doi: 10.1056/NEJMoa1200225 PMC3372918 22449319 · DOI · Paper page
  159. [177]Pournaras DJ Aasheim ET Søvik TT Andrews R Mahon D Welbourn R. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. J Br Surg (2012) 99(1): 100–3. doi: 10.1002/bjs.7704 22021090 · DOI
  160. [178]Holst JJ Madsbad S Bojsen-Møller KN Svane MS Jørgensen NB Dirksen C. Mechanisms in bariatric surgery: gut hormones, diabetes resolution, and weight loss. Surg Obes Related Dis (2018) 14(5): 708–14. doi: 10.1016/j.soard.2018.03.003 PMC5974695 29776493 · DOI
  161. [179]Nduma BN Mofor KA Tatang JT Ekhator C Ambe S Fonkem E. Endoscopic gastric sleeve: A review of literature. Cureus (2023) 15(3): e36353. doi: 10.7759/cureus.36353 37082499 PMC10112045 · DOI
  162. [180]Hedjoudje A Dayyeh BKA Cheskin LJ Adam A Neto MG Badurdeen D. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2020) 18(5): 1043–53. doi: 10.1016/j.cgh.2019.08.022 31442601 · DOI
  163. [181]Jirapinyo P McCarty TR Dolan RD Shah R Thompson CC. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2022) 20(3): 511–24. doi: 10.1016/j.cgh.2021.03.017 33727164 · DOI · Paper page
  164. [182]Sharaiha RZ Hajifathalian K Kumar R Saunders K Mehta A Ang B. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol (2021) 19(5): 1051–7. doi: 10.1016/j.cgh.2020.09.055 33011292 · DOI
  165. [183]Salomone F Sharaiha RZ Boškoski I. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives. Liver Int (2020) 40(6): 1262–8. doi: 10.1111/liv.14441 32181573 · DOI
  166. [184]Jirapinyo P Haas AV Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care (2018) 41(5): 1106–15. doi: 10.2337/dc17-1985 29678867 · DOI
  167. [185]Betzel B Homan J Aarts EO Janssen IM de Boer H Wahab PJ. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg endosc (2017) 31: 2881–91. doi: 10.1007/s00464-016-5299-6 27804045 · DOI
  168. [186]Zechmeister-Koss I Huić M Fischer S European Network for Health Technology Assessment (EUnetHTA). The duodenal–jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg (2014) 24: 310–23. doi: 10.1007/s11695-013-1137-2 24293185 · DOI
  169. [187]Patel SR Hakim D Mason J Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Related Dis (2013) 9(3): 482–4. doi: 10.1016/j.soard.2013.01.015 23452926 · DOI
  170. [188]Brown E Cuthbertson DJ Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides (2018) 100: 61–7. doi: 10.1016/j.peptides.2017.12.009 29412833 · DOI
  171. [190]Bendotti G Montefusco L Lunati ME Usuelli V Pastore I Lazzaroni E. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res (2022) 182: 106320. doi: 10.1016/j.phrs.2022.106320 35738455 · DOI · Paper page
  172. [191]Seufert J Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab (2014) 16(8): 673–88. doi: 10.1111/dom.12251 24373150 · DOI · Paper page
  173. [192]Guo M Gu J Teng F Chen J Ma X Chen Q. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine (2020) 67: 294– 304. doi: 10.1007/s12020-019-02175-6 31900793 · DOI
  174. [193]Brown E Wilding JP Barber TM Alam U Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev (2019) 20(6): 816–28. doi: 10.1111/obr.12841 30972878 · DOI
  175. [194]Thomas MC Coughlan MT Cooper ME. The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metab (2023) 35(2): 253–73. doi: 10.1016/j.cmet.2023.01.004 36754019 · DOI
  176. [195]Napoli R Berra C Catarig AM Di Loreto C Donatiello E Berentzen TL. Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab (2023) 25(6): 1658–67. doi: 10.1111/dom.15020 36789682 · DOI
  177. [196]Foley P Steinberg D Levine E Askew S Batch BC Puleo EM. Track: a randomized controlled trial of a digital health obesity treatment intervention for medically vulnerable primary care patients. Contemp Clin trials (2016) 48: 12– 20. doi: 10.1016/j.cct.2016.03.006 26995281 PMC4885789 · DOI
  178. [197]Rhee SY Kim C Shin DW Steinhubl SR. Present and future of digital health in diabetes and metabolic disease. Diabetes Metab J (2020) 44(6): 819–27. doi: 10.4093/dmj.2020.0088 PMC7801756 33389956 · DOI · Paper page
  179. [198]Iyengar V Wolf A Brown A Close K. Challenges in diabetes care: can digital health help address them? Clin Diabetes (2016) 34(3): 133–41. doi: 10.2337/diaclin.34.3.133 PMC5019009 27621530 · DOI
  180. [199]Soltero EG Lopez C Musaad SM O'Connor TM Thompson D. Fit24, a digital health intervention to reduce type 2 diabetes risk among Hispanic youth: Protocol for a feasibility pilot study. Contemp Clin Trials (2023) 127: 107117. doi: 10.1016/j.cct.2023.107117 36775009 PMC10065958 · DOI

Cited by

Sorted by citations

Authors
Chen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z.
Affiliations
  • Hunan University of Traditional Chinese Medicine (CN)
  • National Centre for Research (Sudan) (SD)
ORCID
Chen, Yan-kun
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2023-08-01
Volume
14
Pages
1218880-1218880
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2023.1218880
PMC
PMC10433171
OpenAlex
W4385444362
Cited by
74
References
15
Citations by year
2026: 16 · 2025: 43 · 2024: 14 · 2023: 1
FWCI
3.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
  • Health Sciences › Medicine › Complementary and alternative medicine › Medical Research and Treatments
Keywords
obesity, diabetes mellitus, traditional Chinese medicine, acupuncture, herbal medicine, dietary therapy, gut microbiota, inflammation, insulin sensitivity, weight loss, antidiabetic drugs, GLP-1 receptor agonists, SGLT2 inhibitors, anti-obesity drugs, metabolic disorders
MeSH terms
Gastrointestinal Microbiome, Diabetes Mellitus, Humans, Medicine, Chinese Traditional, Obesity, Acupuncture, Herbal Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review